PanOptica

PanOptica, Inc. was co-founded by Paul Chaney, past president of OSI Eyetech, and Martin Wax, M.D., former vice president of R&D and head of discovery research and preclinical sciences at Alcon. In early 2009, PanOptica officially began operating as a venture-backed private biopharmaceutical company with seed financing from SV Life Sciences.
Since then, guided by the deep and complementary experience of its founders, PanOptica has identified and evaluated more than 70 assets with the goal of licensing and developing a portfolio of exciting and innovative therapeutics for major ophthalmic disease. In early 2011, PanOptica announced that it had raised $30 million in a Series A financing, led by two leading healthcare venture firms: SV Life Sciences and Third Rock Ventures.